ATE390134T1 - (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen - Google Patents
(+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungenInfo
- Publication number
- ATE390134T1 ATE390134T1 AT01939312T AT01939312T ATE390134T1 AT E390134 T1 ATE390134 T1 AT E390134T1 AT 01939312 T AT01939312 T AT 01939312T AT 01939312 T AT01939312 T AT 01939312T AT E390134 T1 ATE390134 T1 AT E390134T1
- Authority
- AT
- Austria
- Prior art keywords
- piperidinemethanol
- dimethoxyphenyl
- prodrug
- fluorophenyl
- alpha
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- HXTGXYRHXAGCFP-UHFFFAOYSA-N volinanserin Chemical compound COC1=CC=CC(C(O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20694300P | 2000-05-25 | 2000-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE390134T1 true ATE390134T1 (de) | 2008-04-15 |
Family
ID=22768607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01939312T ATE390134T1 (de) | 2000-05-25 | 2001-05-23 | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20020099076A1 (de) |
| EP (1) | EP1289527B1 (de) |
| JP (1) | JP2003535058A (de) |
| KR (1) | KR100784655B1 (de) |
| CN (1) | CN1436078A (de) |
| AR (1) | AR029666A1 (de) |
| AT (1) | ATE390134T1 (de) |
| AU (2) | AU2001264842B2 (de) |
| BR (1) | BR0111102A (de) |
| CA (1) | CA2410554C (de) |
| DE (1) | DE60133385T2 (de) |
| DK (1) | DK1289527T3 (de) |
| ES (1) | ES2300333T3 (de) |
| IL (1) | IL152908A0 (de) |
| MX (1) | MXPA02011511A (de) |
| NO (1) | NO20025630L (de) |
| NZ (1) | NZ522659A (de) |
| PT (1) | PT1289527E (de) |
| TW (1) | TWI299001B (de) |
| WO (1) | WO2001089498A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2492924C (en) | 2002-07-19 | 2011-12-20 | Biovitrum Ab | Novel piperazinone derivates for the treatment of 5-ht2a receptor-related disorders |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| CN102114244A (zh) * | 2004-09-30 | 2011-07-06 | 弗·哈夫曼-拉罗切有限公司 | 治疗认知障碍的组合物和方法 |
| DE102006040278A1 (de) * | 2006-08-21 | 2008-03-20 | Technische Universität Dresden | Arzneimittel zur Behandlung des Charles-Bonnet-Syndroms |
| PL3325444T3 (pl) | 2015-07-20 | 2021-12-06 | Acadia Pharmaceuticals Inc. | Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| EP3436010B1 (de) * | 2016-03-29 | 2021-03-10 | Acadia Pharmaceuticals Inc. | Inverse 5-ht2a-serotonin-rezeptor-agonisten oder -antagonisten zur verwendung in der verringerung von amyloid-beta-peptiden und in der verringerung der akkumulation von amyloid-plaques |
| WO2018118626A1 (en) | 2016-12-20 | 2018-06-28 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
| WO2018200977A1 (en) | 2017-04-28 | 2018-11-01 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783471A (en) * | 1985-07-02 | 1988-11-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine methanol derivatives and the uses thereof |
| US4912117A (en) * | 1985-07-02 | 1990-03-27 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds |
| US5169096A (en) * | 1985-07-02 | 1992-12-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl-piperidine-methanol derivatives |
| US5021428A (en) * | 1985-07-02 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds for the prophylactic treatment of migraine |
| US4877798A (en) * | 1987-11-23 | 1989-10-31 | Merrell Dow Pharmaceuticals Inc. | Treatment of fibromyalgia |
| ATE102482T1 (de) * | 1988-01-21 | 1994-03-15 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit. |
| US5106855A (en) * | 1989-12-20 | 1992-04-21 | Merrell Dow Pharmaceuticals Inc. | Method for the treatment of glaucoma |
| KR100211713B1 (ko) * | 1990-06-01 | 1999-08-02 | 슈테펜 엘. 네스비트 | (+)-알파-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올 |
| US6004980A (en) * | 1990-06-01 | 1999-12-21 | Merrell Pharmaceuticals, Inc. | (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
| US5618824A (en) * | 1994-03-09 | 1997-04-08 | Merrell Pharmaceuticals Inc. | Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
| FR2738819B1 (fr) * | 1995-09-14 | 1997-12-05 | Sanofi Sa | Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant |
| EP0796619A1 (de) * | 1996-03-21 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-Fluorophenyl)ethyl)-4-Piperidinmethanol zur Behandlung von Depressionen und bipolaren Erkrankungen |
| US6028083A (en) * | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
| WO1999020315A1 (en) * | 1997-10-23 | 1999-04-29 | The Research Foundation Of State University Of New York | Methods of screening potential atypical antipsychotic drugs |
| JP2002523460A (ja) | 1998-08-28 | 2002-07-30 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 睡眠障害の治療のためのＲ−（＋）−α−（２，３−ジメトキシフェニル）−１−［２−（４−フルオロフェニル）エチル］−４−ピペリジンメタノールの使用 |
| PL193306B1 (pl) * | 1998-10-14 | 2007-01-31 | Aventis Pharma Inc | Estry (+)-alfa-(2,3-dimetoksyfenylo)-1-[2-(4-fluorofenylo)-etylo]-4-piperydynometanolu, sposób ich wytwarzania i ich zastosowanie oraz kompozycja farmaceutyczna je zawierająca |
| US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
-
2001
- 2001-05-18 US US09/861,980 patent/US20020099076A1/en not_active Abandoned
- 2001-05-23 DK DK01939312T patent/DK1289527T3/da active
- 2001-05-23 NZ NZ522659A patent/NZ522659A/en unknown
- 2001-05-23 AR ARP010102464A patent/AR029666A1/es unknown
- 2001-05-23 EP EP01939312A patent/EP1289527B1/de not_active Expired - Lifetime
- 2001-05-23 CA CA002410554A patent/CA2410554C/en not_active Expired - Fee Related
- 2001-05-23 AT AT01939312T patent/ATE390134T1/de not_active IP Right Cessation
- 2001-05-23 PT PT01939312T patent/PT1289527E/pt unknown
- 2001-05-23 CN CN01810983A patent/CN1436078A/zh active Pending
- 2001-05-23 MX MXPA02011511A patent/MXPA02011511A/es active IP Right Grant
- 2001-05-23 WO PCT/US2001/016653 patent/WO2001089498A2/en active IP Right Grant
- 2001-05-23 AU AU2001264842A patent/AU2001264842B2/en not_active Ceased
- 2001-05-23 IL IL15290801A patent/IL152908A0/xx unknown
- 2001-05-23 TW TW090112318A patent/TWI299001B/zh not_active IP Right Cessation
- 2001-05-23 DE DE60133385T patent/DE60133385T2/de not_active Expired - Fee Related
- 2001-05-23 AU AU6484201A patent/AU6484201A/xx active Pending
- 2001-05-23 BR BR0111102-7A patent/BR0111102A/pt not_active Application Discontinuation
- 2001-05-23 JP JP2001585743A patent/JP2003535058A/ja active Pending
- 2001-05-23 ES ES01939312T patent/ES2300333T3/es not_active Expired - Lifetime
- 2001-05-23 KR KR1020027015968A patent/KR100784655B1/ko not_active Expired - Fee Related
-
2002
- 2002-08-13 US US10/217,843 patent/US20030036553A1/en not_active Abandoned
- 2002-11-22 NO NO20025630A patent/NO20025630L/no not_active Application Discontinuation
-
2004
- 2004-05-03 US US10/838,035 patent/US7132433B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TWI299001B (en) | 2008-07-21 |
| BR0111102A (pt) | 2003-03-11 |
| AR029666A1 (es) | 2003-07-10 |
| MXPA02011511A (es) | 2003-04-25 |
| US20030036553A1 (en) | 2003-02-20 |
| US20020099076A1 (en) | 2002-07-25 |
| CA2410554C (en) | 2009-02-03 |
| CN1436078A (zh) | 2003-08-13 |
| NO20025630L (no) | 2003-01-24 |
| NZ522659A (en) | 2004-06-25 |
| DK1289527T3 (da) | 2008-07-14 |
| DE60133385D1 (de) | 2008-05-08 |
| WO2001089498A2 (en) | 2001-11-29 |
| DE60133385T2 (de) | 2009-04-23 |
| NO20025630D0 (no) | 2002-11-22 |
| PL359176A1 (en) | 2004-08-23 |
| US20040204457A1 (en) | 2004-10-14 |
| EP1289527B1 (de) | 2008-03-26 |
| WO2001089498A3 (en) | 2002-05-10 |
| US7132433B2 (en) | 2006-11-07 |
| KR100784655B1 (ko) | 2007-12-12 |
| PT1289527E (pt) | 2008-05-13 |
| AU2001264842B2 (en) | 2005-01-27 |
| ES2300333T3 (es) | 2008-06-16 |
| JP2003535058A (ja) | 2003-11-25 |
| IL152908A0 (en) | 2003-06-24 |
| AU6484201A (en) | 2001-12-03 |
| EP1289527A2 (de) | 2003-03-12 |
| CA2410554A1 (en) | 2001-11-29 |
| KR20030034078A (ko) | 2003-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE250605T1 (de) | Piperidin verbindung zur behandlung von psoriasis | |
| DE60132777D1 (de) | Benzothiazolderivate zur behandlung von alzheimer und parkinson | |
| DE60234760D1 (de) | Phenylindole zur behandlung von hiv | |
| DE60219292D1 (de) | Pyrazolderivate zur behandlung von hiv | |
| DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| ATE275145T1 (de) | Chinazolinderivate zur behandlung von tumoren | |
| DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| DE60208221D1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
| ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
| DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| NO20014047D0 (no) | Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser | |
| DE60113496D1 (de) | Verwendung von Glycyrrhizin zur Behandlung von Mastitis. | |
| DE69934877D1 (de) | Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen | |
| NO20034311D0 (no) | CCR5-antagonister for behandling av AIDS | |
| NO20043085L (no) | Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet | |
| DE69925865D1 (de) | 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| DE602004003952D1 (de) | Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders | |
| DE502004010131D1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
| ATE369130T1 (de) | Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen | |
| DE60130365D1 (de) | Die Verwendung von Rosiglitazon zur Behandlung von psychiatrischen Erkrankungen. | |
| ATE390134T1 (de) | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen | |
| DE60238765D1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| ID27214A (id) | Triazolopiridina untuk pengobatan gangguan trombosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1289527 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |